Allarity Therapeutics, Inc. Increase (Decrease) in Income Taxes Receivable
Allarity Therapeutics, Inc. (ALLR) reported Increase (Decrease) in Income Taxes Receivable of $444.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2026-08-14
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for the quarter ending 2026-06-30 was $228.00K, a 53.85% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for the quarter ending 2026-03-31 was $216.00K, a 37.39% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for the quarter ending 2025-12-31 was -$796.00K.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for the quarter ending 2025-09-30 was $53.00K, a 27.40% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for fiscal 2025 was $96.00K.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for fiscal 2024 was -$45.00K, a 273.08% decline from fiscal 2023.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for fiscal 2023 was $26.00K.
- Allarity Therapeutics, Inc. increase (decrease) in income taxes receivable for fiscal 2020 was $104.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $444.00K 10-Q · filed 2026-08-14 | -$352.00K derived: sum of 3 quarters · filed 2026-08-14 | -$299.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $216.00K 10-Q · filed 2026-05-15 | -$580.00K derived: sum of 2 quarters · filed 2026-05-15 | -$527.00K derived: sum of 3 quarters · filed 2026-05-15 | -$33.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$796.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$743.00K derived: sum of 2 quarters · filed 2026-03-30 | -$249.00K derived: sum of 3 quarters · filed 2026-08-14 | $96.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $547.00K derived: sum of 2 quarters · filed 2026-08-14 | $892.00K 10-Q · filed 2025-11-14 | $10.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $839.00K 10-Q · filed 2026-08-14 | -$43.00K derived: sum of 3 quarters · filed 2026-08-14 | $30.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $345.00K 10-Q · filed 2026-05-15 | -$537.00K derived: sum of 2 quarters · filed 2026-05-15 | -$464.00K derived: sum of 3 quarters · filed 2026-05-15 | -$216.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$882.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$809.00K derived: sum of 2 quarters · filed 2026-03-30 | -$561.00K derived: sum of 3 quarters · filed 2026-03-30 | -$45.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $321.00K derived: sum of 2 quarters · filed 2025-11-14 | $837.00K 10-Q · filed 2025-11-14 | $89.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $764.00K 10-Q · filed 2025-08-15 | $16.00K derived: sum of 3 quarters · filed 2025-08-15 | $28.00K derived: sum of 4 quarters · filed 2025-08-15 |
| 2024-03-31 | $516.00K 10-Q · filed 2025-05-09 | -$232.00K derived: sum of 2 quarters · filed 2025-05-09 | -$220.00K derived: sum of 3 quarters · filed 2025-05-09 | $519.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$748.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$736.00K derived: sum of 2 quarters · filed 2025-03-31 | $3.00K derived: sum of 3 quarters · filed 2025-03-31 | $26.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $751.00K derived: sum of 2 quarters · filed 2024-11-14 | $774.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $739.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $762.00K 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $23.00K 10-Q · filed 2024-05-14 | |||
| 2022-09-30 | $194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $332.00K derived: sum of 2 quarters · filed 2023-11-14 | $787.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $593.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $455.00K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $186.00K derived: sum of 2 quarters · filed 2022-11-14 | $589.00K 10-Q · filed 2022-11-14 | $947.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $474.00K 10-Q · filed 2022-10-07 | $832.00K derived: sum of 3 quarters · filed 2022-10-07 | |
| 2021-03-31 | $403.00K 10-Q · filed 2022-05-27 | $761.00K derived: sum of 2 quarters · filed 2022-05-27 | ||
| 2020-12-31 | $358.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $104.00K 10-K · filed 2022-05-17 | ||
| 2020-09-30 | -$254.00K 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |